Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children by Belo, V. A. et al.
  Universidade de São Paulo
 
2012
 
Matrix metalloproteinase-9 genetic variations
affect MMP-9 levels in obese children
 
 
INTERNATIONAL JOURNAL OF OBESITY, LONDON, v. 36, n. 1, pp. 69-75, JAN, 2012
http://www.producao.usp.br/handle/BDPI/42622
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Farmacologia - FMRP/RFA Artigos e Materiais de Revistas Científicas - FMRP/RFA
PEDIATRIC ORIGINAL ARTICLE
Matrix metalloproteinase-9 genetic variations affect
MMP-9 levels in obese children
VA Belo1, DC Souza-Costa2, MR Luizon3, CMM Lanna4, PC Carneiro3, TC Izidoro-Toledo3,
KC Ferraz1 and JE Tanus-Santos3
1Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil; 2Department
of Pharmacology, Federal University of Juiz de Fora, Juiz de Fora, Brazil; 3Department of Pharmacology, Faculty of
Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil and 4Department of Physiology, Federal
University of Juiz de Fora, Juiz de Fora, Brazil
Objective: Matrix metalloproteinase-9 (MMP-9) is involved in the atherosclerotic process and functional polymorphisms in the
MMP-9 gene affect MMP-9 expression/activity, and are associated with cardiovascular diseases. However, no study has tested
the hypothesis that functional MMP-9 polymorphisms could affect MMP-9 levels in obese children. We investigated whether
three MMP-9 gene polymorphisms (C-1562T (rs3918242), 90(CA)(1424) (rs2234681) and Q279R (rs17576)), or haplotypes,
affect MMP-9 levels in obese children.
Methods: We studied 175 healthy control children and 127 obese children. Plasma MMP-9, tissue inhibitor of MMPs (TIMP)-1
and adiponectin concentrations were measured using enzyme-linked immunosorbent assay.
Results: We found similar MMP-9 genotypes, allelic and haplotypes distributions in the two study groups (P40.05). However,
we found lower plasma MMP-9 concentrations in obese subjects carrying the CC or the QQ genotypes for the C-1562T and the
Q279R polymorphisms, respectively, in obese children compared with children with the other genotypes, or with non-obese
children with the same genotypes (all Po0.05). Moreover, we found lower MMP-9 levels and lower MMP-9/TIMP-1 ratios
(which reflect net MMP-9 activity) in obese children carrying the H2 haplotype (which combines the C, H and Q alleles for the
three polymorphisms, respectively) when compared with obese children carrying the other haplotypes, or with non-obese
children carrying the same haplotype (Po0.05).
Conclusions: Our findings show that MMP-9 genotypes and haplotypes affect MMP-9 levels in obese children and adolescents,
and suggest that genetic factors may modify relevant pathogenetic mechanisms involved in the development of cardiovascular
complications associated with obesity in childhood.
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Introduction
Obesity is reaching epidemic proportions worldwide, and its
prevalence is increasing among children and adolescents,
likely accelerating the development of cardiovascular
diseases and promoting premature death in adults.1 There
is now evidence indicating that the extent of atherosclerotic
lesions in children and young adults correlate positively with
body mass index.2 Therefore, the identification of key
pathogenetic mechanisms and genetic markers underlying
such mechanisms may help to prevent the cardiovascular
complications associated with obesity.
Matrix metalloproteinase-9 (MMP-9) is an endopeptidase
capable of degrading components of extracellular matrix and
other substrates. Altered expression and activity of MMP-9
and its major endogenous inhibitor, the tissue inhibitor of
MMPs (TIMP)-1, have been implicated in atherosclerotic
vascular remodeling.3 In fact, experimental and clinical
studies have clearly shown that MMP-9 is highly expressed
in the atherosclerotic plaques,4,5 and elevated MMP-9 levels
have been shown in patients with atherosclerotic diseases.6,7
Importantly, functional genetic polymorphisms in the MMP-
9 gene modify MMP-9 levels and prognosis of patients with
cardiovascular diseases.6,8,9
Although MMP-9 is a major factor in cardiovascular
diseases, there are few studies examining possible alterations
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in MMP-9 and TIMP-1 levels in obese children.10–12 In
addition, no previous study has tested the hypothesis that
functional MMP-9 polymorphisms could affect MMP-9 levels
in obese children and adolescents. In the present study, we
aimed at investigating whether MMP-9 gene polymorphisms
or haplotypes (combinations of genetic markers) affect
MMP-9 levels in obese children and adolescents. We studied
three functional MMP-9 polymorphisms that are known to
modify MMP-9 expression or activity,8,13,14 and have been
associated with cardiovascular diseases:6,8,9,15,16 the C-1562T
(rs3918242) single nucleotide polymorphism and the micro-
satellite (CA)1424 at 90 position (rs2234681), both in
the promoter region of the MMP-9 gene, and the Q279R
single nucleotide polymorphism (rs17576) in the exon 6.
In addition, we have also assessed plasma thiobarbituric
acid-reactive species (TBARS) levels (an index of oxidative
stress), the homeostatic model assessment insulin resistance
(HOMA IR) index and adiponectin levels in the subjects
included in the present study, because we hypothesized that
MMP-9 polymorphisms would not significantly affect these
relevant biomarkers, although we supposed that they would
affect MMP-9 levels.
Methods
Subjects
This study was approved by the Institutional Review Board at
the Federal University of Juiz de Fora, Juiz de Fora, Brazil.
Parents and children were informed as to nature and purpose
of the study. Parents gave their written consent and children
gave their verbal consent.
Study populations consisted of 127 normotensive obese
subjects (57 self reported as white and 70 self reported as
black) recruited from the Endocrinology Ambulatory of the
Adolescent and Child Institute at Juiz de Fora and from the
Childhood Endocrinology Ambulatory of the IMEPEN
Foundation at Juiz de Fora as outpatients. The control group
consisted of 175 healthy children and adolescents (96 self
reported as white and 79 self reported as black) recruited
from the local community and unrelated to the obese
patients.
All children underwent physical examination. Height was
measured to the nearest 0.1 cm by using a wall-mounted
stadiometer. Body weight was measured with a digital
scale to the nearest 0.1 kg. Body mass index was calculated
as the weight in kilograms divided by height in meters
squared. Obesity was defined as body mass index greater
than the 95th percentile, matched according to age and
sex.17 Systolic and diastolic blood pressures were measured
at least three times after more than 15min of rest, and
the presence of hypertension was defined as systolic blood
pressure and/or diastolic blood pressure exceeding the
95th percentile.18 Children with hypertension were not
included in this study, because hypertension may affect
MMP concentrations.19
At the time of clinical attendance, venous blood samples
were collected and genomic DNA was extracted from the
cellular component of 1ml of whole blood by a salting-out
method and stored at 20 1C until analyzed.
Laboratory analyses
Glucose concentrations and lipid parameters (total choles-
terol, triglycerides, high-density lipoprotein cholesterol)
were determined in plasma and serum, respectively, with
routine enzymatic methods using commercial kits (Labtest
Diagnostic SA, Lagoa Santa, Brazil). Low-density lipoprotein
concentration was calculated according to the Friedewald
formula. TBARS levels were determined by a fluorimetric
method as previously described.20
Enzyme immunoassays of MMP-9, TIMP-1, adiponectin and
insulin
Venous blood samples were collected after overnight (8–12h)
fasting, immediately centrifuged at 2000 g for 10min at room
temperature, and plasma samples were stored at 70 1C until
analyzed. MMP-9, TIMP-1 and adiponectin concentrations
were measured in EDTA-plasma, using commercially available
enzyme-linked immunosorbent assay kits (R&D Systems,
Minneapolis, MN, USA) according to manufacturer’s instruc-
tions. Insulin concentrations were measured in EDTA-plasma
using a kit (Genese Produtos Diagnosticos, Sao Paulo, Brazil).
The estimate of insulin resistance obtained by HOMA IR was
calculated as previously described.21
DNA isolation and genotype analyses
Genotypes for the (C-1562T) polymorphism of MMP-9 were
determined by PCR amplification using the primers 50-GCC
TGG CAC ATA GTA GGC CC-30 (sense) and 50-CTT CCT AGC
CAG CCG GCA TC-30 (antisense), and PCR conditions as
previously described.22,23 The amplified products were
digested with Sph I (New England Biolabs, Ipswich, MA,
USA) overnight at 37 1C, producing fragments of 247 bp and
188bp in the case of a polymorphic variant (allele T), or an
undigested 435-bp fragment in the case of a wild-type allele
(allele C). Fragments were separated by electrophoresis in
12% polyacrylamide gels and visualized by silver staining.
To determine the genotypes for the 90(CA)14–24 poly-
morphism, a PCR was carried out using the primers: 50-GAC
TTG GCA GTG GAG ACT GCG GGC A-30 (sense) and 50-GAC
CCC ACC CCT CCT TGA CAG GCA A-30 (antisense). The
PCR conditions were performed as previously described,22,23
and the amplified products were separated in a 7%
polyacrylamide-urea gel and visualized by silver staining.
Differences in molecular weight (or number of bases), from
146bp (CA 14 repeats) to 166 bp (CA 24 repeats), were
determined by comparison with migration of a 10-bp DNA
ladder (Invitrogen, Carlsbad, CA, USA) and with some
samples from homozygotes that were sequenced. The alleles
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for the microsatellite 90(CA)14–24 polymorphism were
classified as ‘low’ (L) count when the number of CA repeats
was less than 21, and as ‘high’ (H) when the number of CA
repeats was 21 or more.22,23 Genotypes of Q279R (rs17576)
were determined using TaqMan Allele Discrimination assay
(Applied Biosystems, Foster City, CA, USA). The PCR
conditions were performed according to the manufacturer’s
instructions.
Statistical analysis
The clinical and laboratorial characteristics of obese patients
and controls were compared by unpaired t-test (normally
distributed variables) or Mann–Whitney test (not normally
distributed variables). The categorical variables were com-
pared between groups by w2-tests. The distribution of
genotypes for each polymorphism was assessed for deviation
from the Hardy–Weinberg equilibrium, and differences in
genotype frequency and in allele frequency between groups
were assessed using w2-tests. A value of Po0.05 was
considered statistically significant.
The Haplo.stats package (version 1.4.4; http://cran.
r-project.org/web/packages/haplo.stats/index.html) was used
to estimate the haplotype frequencies. The haplo.em func-
tion computes maximum likelihood estimates of haplotype
probabilities using the progressive insertion algorithm. The
haplo.score function was used to compute haplotype-specific
score statistics to test for association.24 Only the haplotypes
with frequencies greater than 2% were taken into considera-
tion for the haplotype-specific score analysis. The haplo.cc
function was also used to calculate odds ratio and 95%
confidence intervals for each haplotype. The haplotypes
including genetic variants of three MMP-9 polymorphisms
(C-1562T, 90(CA)1424 and Q279R) were: H1 (CLQ), H2
(CHQ), H3 (CHR), H4 (THR), H5 (TLR), H6 (CLR), H7 (THQ),
and H8 (TLQ). Differences in haplotype frequency were
further tested using a contingency table, and a value of
Po0.00625 (0.05/number of haplotypes, 8; Bonferroni’s
correction) was considered significant to correct for the
number of comparisons made.
To examine the effects of genotypes and haplotype on
circulating levels of MMP-9, TIMP-1 and on MMP-9/TIMP-1
ratios, adiponectin, insulin and TBARs levels in the two
study groups, we used the Kruskall–Wallis test followed by
Dunn’s multiple comparison test (not normally distributed
variables) or analysis of variance, followed by Tukey’s test
(normally distributed variables). However, the H5, H6, H7
and H8 haplotypes were excluded from this analysis, because
they were very rare.
Finally, to further examine the effects of MMP-9 haplo-
types on MMP-9 levels, we have also performed an additional
analysis. We compared MMP-9 haplotypes distributions in
two groups of obese subjects: the lower quartile (LOWER-Q)
group, which included subjects in the lower quartile of
plasma MMP-9 distribution, and the upper quartile (UPPER-Q)
group, which included subjects in the upper quartile of
plasma MMP-9 distribution. We hypothesized that the
haplotypes associated with lower MMP-9 levels in our initial
analysis would be more commonly found in the LOWER-Q
group than in the UPPER-Q group.
Results
The clinical and laboratorial characteristics of the study
groups are presented in Table 1. Higher body mass index
values were found in the obese group as compared with the
control group (26.1±4.3 kgm2 versus 18.3±2.9 kgm2;
Po0.05). Obese subjects had higher arterial blood pressure,
fasting insulin, HOMA IR index, TBARS, low-density lipo-
protein cholesterol and triglycerides, and lower adiponectin
and high-density lipoprotein cholesterol than control sub-
jects (all Po0.05; Table 1).
We found no significant differences in MMP-9 concentra-
tions and in MMP-9/TIMP-1 ratios when obese subjects were
compared with controls (P40.05; Figures 1a or c). However,
obese subjects had lower plasma TIMP-1 concentrations than
control subjects (Po0.05; Figure 1b).
Supplementary Table 1 shows MMP-9 genotypes and allele
frequency distributions in the two study groups. The
distribution of genotypes for each polymorphism studied
here showed no deviation from Hardy–Weinberg equili-
brium, except for the Q279R single nucleotide polymorph-
ism in obese patients, a finding that may be expected in cases
of case–control studies.25 No deviation from Hardy–Wein-
berg equilibrium was observed when considering only black
or only white subjects within each study group.
To examine possible effects of ethnicity on MMP-9 geno-
types distribution, we carried out two different analyses. The
first analysis included black and white children and adoles-
cents, whereas the second analysis took into consideration
Table 1 Clinical characteristics of study participants
Variable Control Obese
N 175 127
Age (years) 11.9±3.1 10.3±2.7*
Ethnicity (% white) 56 48
BMI (kgm2) 18.3±2.9 26.1±4.3*
SBP (mmHg) 105.6±11.5 111.2±10.0*
DBP (mmHg) 65.6±9.0 70.7±8.8*
Fasting glucose (mmol l1) 4.6±0.6 4.7±0.5
Fasting insulin (mU l1) 9.3±4.2 13.0±6.7*
HOMA IR index 1.8±0.9 2.8±1.6*
Adiponectin (ngml1) 13730±578 11 570±617*
TBARS (nmoLml1) 3.9±2.1 5.0±2.3*
Total cholesterol (mgdl1) 141.9±42.6 147.3±40.1
LDL cholesterol (mgdl1) 74.5±23.1 89.0±31.4*
HDL cholesterol (mgdl1) 43.6±8.9 39.1±10.2*
Triglycerides (mgdl1) 76.8±28.7 88.2±43.6*
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HOMA IR, homeostasis model assessment insulin
resistance; TBARS, thiobarbituric acid-reactive species; LDL, low-density
lipoprotein; HDL, high-density lipoprotein. Values are mean±s.d. *Po0.05
vs control.
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only white children and adolescents, which corresponded
to 48–56% of the subjects. Both analyses showed no signi-
ficant differences in genotypes and alleles distributions for
the three MMP-9 polymorphisms between the control group
and obese group (all P40.05; Supplementary Table 1), except
for the Q279R polymorphism. The QR genotype was found
with lower frequency in the obese group compared with
controls (P¼0.038; Supplementary Table 1), and this finding
could be due to significant deviation from Hardy–Weinberg
equilibrium observed in this group. Whereas some minor
differences were detected, we found no statistically signifi-
cant differences in haplotype frequency distributions when
the two groups of subjects were compared (Po0.05;
Supplementary Table 2).
Importantly, we examined the effects of MMP-9 genotypes
on plasma MMP-9 concentrations. With respect to the
C-1562T polymorphism, we found that obese patients with
the CC genotype had lower MMP-9 levels than control
subjects with the same genotype, and lower MMP-9 levels
than obese patients with the CT or TT genotypes (Figure 2a;
both Po0.05). With respect to the 90(CA)1424 polymorph-
ism, we found that obese patients with the HL genotype had
lower MMP-9 levels than control subjects with the same
genotype (Figure 2b; Po0.05). Finally, with respect to the
Q279R polymorphism, we found that obese patients with
the QQ genotype had lower MMP-9 levels than control
subjects with the same genotype, and lower MMP-9 levels
than obese patients with the RR genotype (Figure 2c; both
Po0.05).
In addition, we studied the effects of MMP-9 haplotypes
on MMP-9 and TIMP-1 levels, and on MMP-9/TIMP-1 ratios.
Although no significant differences were found in TIMP-1
levels when the different haplotype groups were compared
(Figure 3b; P40.05), we found lower MMP-9 levels and lower
MMP-9/TIMP-1 ratios in obese subjects with the H2 haplo-
type compared with control subjects carrying the H2
haplotype, or with obese subjects with the H1, H3 or H4
haplotypes (Figures 3a and c; all Po0.05).
Further confirming the haplotype effects on MMP-9 levels,
we found that the H2 haplotype was more commonly found
in obese children and adolescents with lower MMP-9 levels
than in obese subjects with higher MMP-9 levels (Table 2;
P¼0.001).
Finally, we found that MMP-9 genotypes for the three
MMP-9 polymorphisms had no effects on TIMP-1, MMP-9/
TIMP-1, adiponectin, insulin, HOMA IR index and TBARS
levels (Supplementary Table 3; P40.05). Moreover, MMP-9
haplotypes had no effects on adiponectin, insulin and TBARS
levels, and on the HOMA IR index (Supplementary Table 3;
P40.05).
Discussion
The main novel finding reported here was that two
functional MMP-9 genetic polymorphisms affect the circu-
lating MMP-9 levels in obese children and adolescents, either
when considered their single effects or when MMP-9
polymorphisms exert their combined effects within MMP-9
haplotypes. Particularly, lower MMP-9 levels were found in
obese children with the CC genotype for C-1562T poly-
morphism, or with the QQ genotype for Q279R polymorph-
ism, or in subjects carrying the H2 (C H Q) haplotype.
Because MMP-9 levels are associated with cardiovascular
diseases,6,7 our findings suggest that obese children with
these particular MMP-9 genotypes or haplotype may be at
lower risk of developing cardiovascular diseases.
Although increased MMP-9 levels were shown in cardio-
vascular diseases,4–7 we found similar MMP-9 concentrations
and MMP-9/TIMP-1 in obese children compared with non-
obese children. Although this finding confirms previous
Figure 1 Plasma MMP-9 concentrations (a), TIMP-1 concentrations (b) and
MMP-9/TIMP-1 ratios (c) in controls (N¼ 175) and obese (N¼ 127) children
and adolescents. The box and whiskers plots show range and quartiles. The
boxes extend from the 25th percentile to the 75th percentile, with a line at
the median. The whiskers show the highest and the lowest values. *Po0.05 vs
Control group.
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results,12 some authors found increased circulating MMP-9
and TIMP-1 levels in obese children with coexisting
hypertension.10,11 It is possible that hypertension may
explain the discrepancies between studies, because hyperten-
sion may increase MMP-9 levels.19 Interestingly, we found
lower TIMP-1 concentrations and lower adiponectinemia in
obese children compared with non-obese children, and these
findings are consistent with the idea that adiponectin (an
adipose-specific protein and anti-atherogenic factor) mod-
ulates TIMP-1 expression by macrophages.26
Although several polymorphisms have been detected in
the MMP-9 gene, the C-1562T polymorphism increases
MMP-9 expression as a result of loss of a nuclear repressor
protein binding site when the T allele is present.8 The lower
MMP-9 levels that we found in obese subjects not carrying
the T allele is supported by this previous finding. Conversely,
the lack of significant effects of this polymorphism in
Figure 3 Plasma MMP-9 (a) and TIMP-1 (b) levels and MMP-9/TIMP-1
ratios (c) in the control group (C) and in obese children and adolescents (O)
with different MMP-9 haplotypes. The box and whiskers plots show range and
quartiles. The boxes extend from the 25th percentile to the 75th percentile,
with a line at the median. The whiskers show the highest and the lowest
values. *Po0.05 vs the respective control group. #Po0.05 vs obese patients
with the H1, H3 or H4 haplotypes.Figure 2 Plasma MMP-9 levels in the control group (C) and in obese
children and adolescents (O) with different genotypes for MMP-9 polymorph-
isms. Subjects were grouped according to MMP-9 genotypes for the C-1562T
(a), the 90(CA)1424 (b) and the Q279R (c) MMP-9 polymorphisms. The box
and whiskers plots show range and quartiles. The boxes extend from the 25th
percentile to the 75th percentile, with a line at the median. The whiskers show
the highest and the lowest values. *Po0.05 vs the respective control group.
#Po0.05 vs obese patients with the CTþTT genotypes (a), or vs obese
patients with the RR genotype (c).
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non-obese subjects is in line with previous findings showing
that this polymorphism does not affect MMP-9 levels in
healthy subjects.22,23 In addition, we found that absence of
R allele for the Q279R polymorphism was associated with
lower MMP-9 levels in obese children, and this finding
agrees with previous results showing that this polymorphism
affects MMP-9 activity.14 Finally, we found no effects of the
(CA)1424 polymorphism on MMP-9 levels, although there
is evidence that this polymorphism affects MMP-9 expres-
sion.13 Although it is clear that the adipose tissue is an active
endocrine and paracrine organ that releases a large number
of bioactive mediators that could modulate the expression
of MMP-9 gene,27 the present study has not been designed
to define the mechanisms explaining the interactions of
MMP-9 polymorphisms with childhood obesity.
The analysis of haplotypes, rather than single polymor-
phisms, may provide improved genetic information. Here,
we show for the first time that MMP-9 haplotypes may
modulate the circulating MMP-9 levels in obese children and
adolescents. Particularly, obese children carrying the H2 (C H
Q) haplotype had lower MMP-9 levels and lower MMP-9/
TIMP-1 ratios (an index of net MMP-9 activity28) than those
without these genetic markers. Further supporting this find-
ing, the comparison of extreme quartiles of MMP-9 levels
confirmed that the H2 haplotype is associated with lower
circulating MMP-9 levels. Interestingly, these results are in line
with a previous study showing that the H2 haplotype protects
against the development of hypertensive left ventricle hyper-
trophy.9 Together, these findings suggest that lower MMP-9
levels associated with the H2 haplotype could be associated
with protective effects against cardiovascular diseases.
In the present study, we found no association between
MMP-9 genotypes or haplotypes and childhood obesity,
except for the QR genotype, which was apparently more
common in non-obese than in obese subjects. Although this
result is not statistically significant after correction for
multiple comparisons, it could be explained by Hardy–
Weinberg deviation for this polymorphism in obese subjects,
and this finding may be expected in cases of case–control
studies.25 The essentially negative results with respect to the
possible association between MMP-9 polymorphisms and
obesity suggest that, although MMPs have an important role
in the expansion of adipose tissue mass, with intense
extracellular matrix remodeling in obesity,29 genetic markers
involving MMP-9 may not be very relevant to the develop-
ment of childhood obesity.
We found that obese children and adolescents had higher
TBARs levels (a marker of oxidative stress) when compared
with non-obese controls. These results confirm that obesity
is associated with increased oxidative stress and may have
important implications. In fact, oxidative stress is a major
MMPs activator30 and therefore may potentiate MMPs
activities in obese subjects. However, the lack of significant
differences between genotype or haplotype groups, as
reported here, suggest that MMP-9 polymorphisms do not
interact significantly with oxidative stress to modulate MMP-
9 levels in obese subjects.
Although there is evidence that plasma MMP-9 levels are
clearly associated with prognosis in patients with cardiovas-
cular diseases,6 we are not sure about the origin of circulating
MMP-9. Therefore, it is not clear at this time what does it
mean to have variations in MMP-9 plasma levels. Although
further studies linking MMP-9 levels with relevant clinical
events are necessary, an important implication of the present
findings is that obese children with the CC or with the QQ
genotypes for the C-1562T and the Q279R polymorphisms,
respectively, or those with the H2 haplotype, may be
protected against the development of cardiovascular diseases
associated with obesity. These findings may suggest that
MMP-9 is a relevant pharmacological target in the preven-
tion of complications associated with obesity. It remains to
be proved whether MMPs inhibitors decrease the incidence
of cardiovascular events in obese subjects without these
genetic markers.
In conclusion, we found evidence indicating that MMP-9
genotypes and haplotypes affect MMP-9 levels in obese
children. Our findings support the notion that genetic
factors may modify relevant pathogenetic mechanisms
involved in the development of cardiovascular complica-
tions associated with obesity in childhood. Further studies
examining the effects of MMP-9 polymorphisms on the
incidence of clinical events in obese children are warranted.
Table 2 MMP-9 haplotypes frequency distributions in the Lower-Q and in the Upper-Q groups of obese patients
Haplotype Hap-score P-values Frequency Lower-Q Upper-Q OR (95% CI)
H1 CLQ 0.019 0.985 0.422 0.427 0.422 1.000 (Reference)
H2 CHQ 3.443 0.001* 0.230 0.322 0.127 0.433 (0.211–0.891)*
H3 CHR 1.155 0.248 0.226 0.201 0.261 1.091 (0.539–2.206)
H4 THR 2.313 0.021 0.087 0.048 0.121 2.663 (0.899–7.886)
H5 TLR NA NA F NA 0 F
H6 CLR 1.682 0.093 0.021 0.000 0.037 F
H7 THQ NA NA F NA 0 F
H8 TLQ NA NA F NA 0 NA
Abbreviations: MMP-9, matrix metalloproteinase-9; Lower-Q, lower quartile; Upper-Q, upper quartile; CI, confidence intervals; OR, odds ratio; NA, not available.
Global-stat¼20.178, df¼5. *P¼0.0011573. A value of Po0.00625 (0.05/number of haplotypes) was considered significant, to correct for the number of
comparisons made in haplotype analysis (Bonferroni’s correction). The Lower-Q group included obese subjects in the lower quartile of plasma MMP-9 distribution,
whereas the Upper-Q group included obese subjects in the upper quartile of plasma MMP-9 distribution.
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